On the ‘red list’ in Vietnam?
Why are pharma companies in India still falling foul of overseas regulators?
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Editor’s Note Archive
Playing the frenemy card
AIDAN’s PIL accusing the DoP of 'browbeating' the NPPA might not be so far-fetched as innovators and generic companies cosy up…
Beyond pricing and patents
Emerging market strategies of Big Pharma have been defined by two Ps: pricing and patents
Rx for NaMo’s next 100 days and beyond
Prime Minister Modi's first 100 days in office may not have quite met the expectations of India Pharma Inc but the cautious…
Adding bite to DCG(I)’s bark
On August 6, the quality assurance (QA) division of the CDSCO had released guidelines on the procedures to be followed by its…
The Ebola effect
The fear of the Ebola Virus Disease (EVD) being imported into India is worrying our Parliamentarians but besides relying on…
India’s loss, China’s gain?
India's drug pricing authority, the National Pharmaceutical Pricing Authority is once again at loggerheads with the industry
Budget 2014: Will implementation live up to intent?
I had ended my last edit with the hope that this year, unlike previous years, the pharmaceutical sector’s hopes would not be as…
Wish upon on a star
Narendra Modi's massive electoral mandate has unfortunately raised expectations; both from the man on the street as well as from…
No easy wins in pharma
As we go to press, the Pfizer-AstraZeneca deal is called off for now but that story is far from over
More to rules than the carrot-and-stick approach
Above revenues and reputation, is patient health and safety. If that's compromised, everything is lost
US, India face off on IP yet again
As we await the US Trade Representative's annual Special 301 Report, stakeholders on both sides of the fence seem to be hardening…
Three more cos face US FDA ire-1
Last month, the US FDA has reportedly issued 483s to at least three more pharmaceutical companies in India, one of them the Indian…
Walking the talk on GCP
“If we are interested in exporting medicines, we have to also import the standards.”
Bitter medicine
Name-Shame-Blame-Train. This has been the pharmaceutical industry's mantra to manage non-compliance
Raising the bar
After visiting the Taj Mahal on her recent visit to India, FDA Commissioner Margaret A Hamburg blogged, “those responsible for…
Recruiting right
Blogging about her recent trip to India, Margaret Hamburg, Commissioner of the US Food and Drug Administration (FDA) spoke about…
Light at the end of the biotech tunnel?
As we go to press with this special issue focussing on the biotechnology sector in India, Biocon's Q3 results seem like a light at…
In search of greener pastures
After hanging fire for the past few months, the Department of Industrial Policy and Promotion (DIPP) has finally given some…